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Abstract 
 
Ubiquitylation is crucial for regulating numerous cellular functions. In the kidney, 
ubiquitylation regulates the epithelial Na+ channel ENaC. The importance of this process is 
highlighted in Liddle’s syndrome, where mutations interfere with its ubiquitylation, resulting 
in constitutive Na+ reabsorption and hypertension. There is emerging evidence that NCC, 
involved in hypertensive diseases, is also regulated by ubiquitylation. Here we discuss the 
current knowledge and recent findings in this field. 
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Introduction  
 
Hypertension is involved in many diseases like stroke, myocardial infarction, heart and 
kidney failure. The kidney and most particularly the segments of the post-macula densa that 
consists in the distal convoluted tubule (DCT), the connecting tube (CNT) and the collecting 
duct (CD), are crucial for controlling Na+/K+ balance and thus extracellular volume and blood 
pressure (98). In the DCT, Na+ reabsorption occurs by electroneutral co-transport via the 
thiazide-sensitive NaCl cotransporter (NCC). In the late part of the DCT (DCT2), Na+ is 
reabsorbed via the electrogenic amiloride-sensitive epithelial Na+ channel (ENaC) in addition 
to NCC. In the CNT and CD, Na+ is reabsorbed via ENaC only (75). ENaC provides the 
driving force for K+ secretion through the renal outer medullary K+ channel (ROMK) (27).  
The significance of tightly regulating ion transport in the renal nephron segments is 
underscored by the fact that blockers of the ion channels and transporters are often used to 
treat hypertension, and by the fact that genetic diseases affecting ENaC and NCC in humans 
lead to impaired Na+ balance and blood pressure. Gain-of-function mutations within ENaC 
cause Liddle's syndrome, characterized by increased ENaC expression and open probability 
(24) and resulting in salt retention and hypertension (89). Indeed, such mutations in β- and 
γENaC interfere with the ubiquitylation and degradation of the channel by the ubiquitin-
protein ligase NEDD4-2, encoded by the Nedd4L gene, and lead to impaired ENaC 
internalization and degradation (2, 29, 37, 38, 94, 96). Mutations in human proteins leading to 
overactive NCC result in pseudohypoaldosteronism type II (PHAII, also referred to as 
Gordon’s syndrome or Familial Hyperkalemic Hypertension, FHHt) (9, 48, 105) and are 
associated with hypertension and a reduced distal delivery of Na+, with consequent 
hyperkalemia (36, 49, 82). These mutations were identified in the genes that encode the with-
no-lysine kinases WNK1 and WNK4, two main regulators of NCC (57). Recently, the groups 
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of Lifton and Jeunemaître have independently shown that mutations in humans affecting the 
genes encoding the kelch-like KLHL3/Cullin 3 (CUL3) ubiquitin-protein ligase complex lead 
to overactive NCC and thus hypertension (9, 48), pointing at the importance of ubiquitylation 
in the regulation of renal Na+ transport. In addition, we have shown both in vitro and in vivo 
that NEDD4-2 is involved in NCC regulation (3, 78). 
In this review, we summarize what is known about the role of ubiquitylation in the regulation 
of ENaC and the recent findings about the regulation of NCC by this process. We also discuss 
the importance of ubiquitylation in the control of Na+ balance and blood pressure.  
 
Regulation of ENaC-mediated Na+ transport by the ubiquitin-ligase NEDD4-2  
Ubiquitylation is a post-translational modification process that is crucial for regulating many 
different cellular functions. Indeed, ubiquitylation is used as a signal for membrane protein 
internalization or degradation by the proteasome or lysosomes (52, 99). Ubiquitin can be 
conjugated as a monoubiquitin or polyubiquitin chains on the amino group of lysine side 
chains. Monoubiquitylation on single or several sites on target proteins is involved in 
numerous biological functions including endocytosis and direction to lysosomal degradation 
(52). Also polyubiquitin chains may have different roles, but the best characterized canonical 
function is the targeting to the proteasome via K48-linked ubiquitins (17, 62).  
Ubiquitylation is performed by several enzymes: an E1 ubiquitin-activating enzyme, E2 
ubiquitin-conjugating enzymes, and E3 ubiquitin-protein ligases. The ubiquitin molecule is 
first activated by the E1 enzyme using ATP, forming first a thioester with the active site of E1 
and then to that of E2. The E3 enzymes, that recognize the target protein, interact with both 
E2 and the substrate and lead to the formation of an isopeptide bond between a lysine of the 
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target protein and the C-terminal glycine of ubiquitin. Hundreds of E3 enzymes participate in 
the target protein recognition and thus provide the specificity to the cascade (65). 
There are two main classes of E3 enzymes. The first class involves E3 ubiquitin-protein 
ligases that contain a RING motif (RING stands for Really Interesting New Gene) that helps 
transferring the ubiquitin from E2 to the target protein (61). This class includes monomeric 
proteins, and multimeric complexes comprising Cullin proteins as platforms that assemble E2 
enzymes, RING motif containing proteins, and adaptor proteins. KLHL3 and CUL3 belong to 
this class, whereby CUL3 represents the platform, and KLHL3 an adaptor protein involved in 
target recognition. The second class is formed by the HECT (homologous to E6-AP C-
terminal) domain-containing E3 ubiquitin-protein ligases that form first a thioester with the 
ubiquitin before transferring it on the substrate (84). The NEDD4/NEDD4-like (Neural 
precursor cell Expressed Developmentally Down-regulated protein)-like family belongs to the 
HECT E3 ligase class and regroups nine proteins: AIP4/ITCH, HecW1/NEDL1, and 
HecW2/NEDL2, NEDD4, NEDD4–2/NEDD4L, SMURF1, SMURF2, WWP1/TIUL1, and 
WWP2 (79). All these proteins contain an N-terminal (Ca2+-dependent lipid binding) C2 
domain for membrane binding (77), a central region containing two to four WW domains for 
interaction with the target protein (100), and a C-terminal HECT domain for binding to 
ubiquitin and transfer on the target (79, 84). Ubiquitylation is a reversible process catalyzed 
by deubiquitylating enzymes (DUBs) (44, 66) 
 
The role of ubiquitylation in the regulation of cell surface expression and endocytosis of ion 
channels and transporters has emerged with the finding that the WW domains of the 
NEDD4/NEDD4-like E3 ligases bind to the proline-rich PY motifs of ENaC (core motif: 
PPXY, where P is a proline, Y a tyrosine, and X any amino-acid), motifs that are deleted in 
Liddle’s syndrome (96) (Figure 1B). In this study, the authors used the PY-containing region 
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of the βENaC subunit as bait in a two-hybrid screen to identify proteins, which interact with 
ENaC, and identified NEDD4-2. It was then shown that each of the three ENaC subunits α, β 
and γ contains a PY motif in the C-terminus (85, 93, 96). Interestingly, NEDD4-2 is expressed 
in tissues that also express ENaC (37). It was proposed that the enhanced cell surface ENaC 
expression observed in Liddle’s patients might be due to a defect in ubiquitylation and 
degradation of the channel (Figure 1C). This hypothesis was confirmed in 1999, by the 
finding that indeed the regulation of ENaC by NEDD4-2 was defective in Liddle’s syndrome 
(2). Another study later showed that the NEDD4-2 WW3-4 domains regulate ENaC (25, 37). 
In 2006, Knight et al. found out that Liddle’s syndrome mutations enhance Na+ transport by 
acting on ENaC surface expression and open probability (41). One year later, Wiemuth et al. 
demonstrated that ENaC is multi-monoubiquitylated at the cell surface (104), and two other 
independent groups showed that the PY motifs on ENaC, that are mutated in Liddle’s 
syndrome, regulate the internalization of the channel, its sorting and recycling (50) and that 
NEDD4-2 catalyzes the plasma membrane ENaC ubiquitylation and degradation (113). 
However, whether ENaC is mono- or poly-ubiquitylated remains controversial. Some groups 
have proposed that ENaC is poly-ubiquitylated and targeted to proteasomal degradation (53-
55), while others suggested that the channel is either mono- or multimono-ubiquitylated at the 
surface of the cell (81, 104, 113). One explanation might be that ENaC is polyubiquitylated in 
the endoplasmic reticulum (ER), in the context of ERAD (ER-associated degradation), where 
misfolded or unassembled proteins are degraded via ubiquitin-proteasome pathway (10), 
whereas the assembled channel expressed at the cell surface is likely degraded via 
endosomal/lysosomal degradation involving multi-monoubiquitylation (97, 112) (Figure 1). 
Direct evidence of ERAD-based regulation of ENaC has been provided by Brodsky and 
collaborators (10).  
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As mentioned above, ubiquitylation is a process that is reversible, catalyzed by DUBs (66). 
ENaC has been proposed to be regulated by several of these DUBs, including USP2-45, 
USP8, USP10 and UCH-L3 (8, 11, 21, 114). Although deubiquitylation of ENaC appears to 
be an appealing concept for ENaC regulation, the physiological relevance of these 
observations remain to be proven, especially as a recent report of a Usp2 knockout model 
provides no evidence for the involvement of USP2 in the control of Na+ homeostasis or blood 
pressure control (71).  
 
To elucidate the relationship between the regulation of ENaC and the control of Na+ balance 
and hypertension, an in vivo model for Liddle’s syndrome was generated by mutating the β 
subunit of the mouse ENaC, resulting in a truncated βENaC as found in Liddle’s patients (73). 
Under high-Na+ diet, these Liddle mice presented the Liddle phenotype characterized by 
higher blood pressure, metabolic alkalosis, and hypokalemia, together with heart and kidney 
hypertrophy. The cell surface density of functional ENaC, but not the open probability, was 
enhanced in the kidneys of Liddle mice (14). In addition, whereas the γENaC subunit was 
rapidly internalized in control mice, it was retained at the plasma membrane of CNT in Liddle 
mice (73). Accordingly, measures in isolated perfused CCD and in confluent primary cultures 
of microdissected CCD isolated from Liddle mice exhibited higher ENaC activity (73).  
 
NEDD4-2-mediated ubiquitylation of ENaC is under the tight control of the mineralocorticoid 
hormone aldosterone, which prevents the interaction between the channel and the ubiquitin-
protein ligase (Figures 1A and B). This is mediated by the serum- and glucocorticoid-induced 
kinase 1 (SGK1): under aldosterone stimulus, SGK1 expression is induced and the kinase 
phosphorylates NEDD4-2, resulting in the recruitment of 14-3-3 proteins that disrupt the 
NEDD4-2/ENaC interaction and subsequent ubiquitylation and degradation of the channel (6, 
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13, 15, 33, 46, 91, 92). A number of alternative mechanisms of regulation by SGK1 or 
NEDD4-2 have also been suggested, including the direct phosphorylation of ENaC by SGK1 
(16), or direct phosphorylation of ENaC by ERK kinase which may facilitate the interaction 
with NEDD4-2 (86). Pearce and collaborators provided evidence for an ENaC regulatory 
complex that comprises NEDD4-2, SGK1, GILZ, RAF-1 and CNK3. It was proposed that the 
complex may integrate the activities of various signaling pathways involved in ENaC 
regulation, including those regarding steroid receptors, PI-3 kinase, mTOR and RAF-MEK-
ERK pathways (95).. Very recently, another novel mode of regulation of ENaC, comprising 
the ubiquitin-like protein NEDD8, was also described (18, 51). 
 
In vivo Nedd4-2 knockout models: new insights in the role of NEDD4-2-mediated 
regulation of Na+ transport and blood pressure  
As described above, genetic mutations in human and in vitro biochemical and overexpression 
studies suggested that the interaction between NEDD4-2 and ENaC is crucial for regulating 
Na+ balance and blood pressure. Moreover, single nucleotide polymorphisms (SNPs) in 
human Nedd4L (that encodes NEDD4-2) have been linked to hypertension (19). To validate 
the role of NEDD4-2 in vivo, several groups have generated in the last few years mouse 
knockout models of Nedd4L (for summary of these mouse models, see Table 1). The first 
model was developed by the group of Baoli Yang. In these Nedd4L knockout mice, the exons 
6 to 8 of the Nedd4L gene were removed in a constitutive manner(Nedd4L-Δ6-8 mice) (87). 
Surprisingly, despite the predicted function of NEDD4-2 as a major regulator of ENaC, the 
Nedd4L-Δ6-8 knockout mice were viable and only displayed cardiac hypertrophy and a mild 
salt-sensitive hypertensive phenotype. The  extracellular volume and Na+/K+ balance were not 
impaired (87). The protein expression of the three subunits of ENaC was enhanced in the 
knockout mice and the increased blood pressure under high-Na+ diet could be treated by 
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injecting amiloride to the mice, suggesting overactive ENaC. However, the plasma 
aldosterone levels were normal under standard and high-Na+ diet, indicating a rather mild 
ENaC-overactivation phenotype.  
Another Nedd4L total knockout model has been generated by Sharan Kumar’s group, by 
deleting exons 15-16 of the Nedd4L gene in the mouse (7). In contrast to Yang’s mice, the 
model of Kumar displayed perinatal lethality resulting from premature fetal lung fluid 
clearance as a consequence of increased ENaC expression and activity in embryonic lungs 
(7). Expression of the three ENaC subunits α, β and γ was increased in lungs and kidneys of 
E18.5 embryos and the amiloride-sensitive ENaC-mediated current was strongly enhanced in 
embryonic knockout lung cells. These data clearly indicate that NEDD4-2 is important for the 
regulation of ENaC in the kidney and that it is a key regulator of ENaC function in the lung, 
leading to lethality when deleted (7). These data also confirmed what was observed in the 
βENaC Liddle mice, in which the mutation in βENaC prevented the down-regulation of the 
channel by NEDD4-2. Indeed, these mice also showed increased alveolar fluid clearance due 
to ENaC overactivity (72-74).  
The same year, the group of Daniela Rotin published another Nedd4L knockout model, but 
this time by inactivating Nedd4L specifically in the lungs (40). This study showed that 
ablating the exon 15 and the downstream region of the Nedd4L gene in mice leads to a 
phenotype resembling lung cystic fibrosis, with airway mucus obstruction, intense 
inflammation and lethality at the age of three weeks. These observations were accompanied 
with increased protein abundance of the three ENaC subunits, enhanced ENaC currents and 
amiloride-sensitive dehydration, and increased dryness of the lungs (40). These results 
confirm what was observed in transgenic mice overexpressing ENaC (56) and confirm the 
crucial role of lung NEDD4-2 in regulating ENaC expression and activity by ubiquitylation. 
Interestingly, Kimura et al. could rescue the lung defects by nasally administrating amiloride 
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to the newly born lung-specific Nedd4L knockout mice, suggesting that the observed lung 
phenotype was resulting from defect in ENaC degradation due to NEDD4-2 ablation (40). 
Very recently, Ronzaud et al. have published a new Nedd4L knockout mouse model, where 
exons 6 to 8 of the Nedd4L gene have been removed (using the same floxed allele as Shi et 
al.) in an inducible and renal tubule-specific manner (Nedd4LPax8/LC1 knockout mice) using a 
combination of the Cre-loxP and Tet-On systems (78). As expected, these mice displayed salt-
sensitive hypertension, decreased plasma aldosterone levels and increased renal β- and γENaC 
protein expression. However, the urine and plasma Na+ and K+ levels were normal in the 
knockout mice. In addition, the cellular localization of β- and γENaC was mainly 
cytoplasmic, and γENaC was found in its uncleaved form. Surprisingly, the Nedd4LPax8/LC1 
knockout mice showed reduced αENaC mRNA levels and proteolytic cleavage, suggesting 
down-regulation of the channel (Figure 1D). Interestingly, the ENaC down-regulation that 
accompanied the reduced plasma aldosterone could be rescued by giving aldosterone to the 
knockouts. Thus, these data confirmed that NEDD4-2 is important for mediating the 
degradation of β- and γENaC, that aldosterone is crucial for regulating renal αENaC 
expression (4), and that αENaC is needed for apical trafficking of the two other ENaC 
subunits (80). Of interest, no mutation in the human αENaC gene was found to cause Liddle’s 
syndrome. In addition, injection of amiloride in Nedd4LPax8/LC1 knockout mice did not reduce 
the elevated blood pressure, indicating that the hypertensive phenotype is not due to increased 
ENaC function. Therefore, the Nedd4LPax8/LC1 knockout mice question the previous in vitro 
and in vivo studies that showed the implication of NEDD4-2-mediated ubiquitylation in the 
regulation of αENaC. 
It is difficult to reconcile the different phenotypes obtained with all these Nedd4L knockout 
mouse models, as they are differing at several levels: genetic background, part of the Nedd4L 
gene that was deleted, targeted tissue, and knockout strategy (constitutive or inducible). 
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However, their comparison opens new questions regarding NEDD4-2 function and tissue-
specificity. First, it should be noted that Shi et al. did not specify whether the observed 
enhanced α, β and γENaC subunits were expressed apically or within the cell. In addition, the 
absence of any decrease in plasma aldosterone is in contrast to what is observed in Liddle’s 
patients. It has been proposed that the absence of lung phenotype and lethality in the Shi et 
al.’s model could be explained by the presence of a shorter Nedd4L splice isoform (7). 
Indeed, the region of the Nedd4L gene that has been deleted in the Shi et al.’s model is known 
to be subjected to differential splicing (34). However, using different antibodies against 
NEDD4-2, Ronzaud et al. were not able to detect any shorter NEDD4-2 isoform in the 
Nedd4LPax8/LC1 knockout mice, at least in the kidney (78). It is also plausible that other 
NEDD4 family members might compensate for the loss of NEDD4-2 in the lung, although 
Ronzaud et al. did not observe any increase in NEDD4-1, the closest family member (78). 
Another possibility could be that the mixed genetic background used in the Shi et al.’s model 
contributes to the milder phenotype of these mice compared to those developed by Kumar and 
Rotin (7, 40).  
Moreover, it is also difficult to reconcile the phenotype of the Nedd4LPax8/LC1 knockout mice 
with what has been observed in mouse models of Liddle’s syndrome, where the activity of 
ENaC is increased despite the low plasma aldosterone and where the three ENaC subunits are 
accumulating in the plasma membrane (72). It is likely that loss of the regulator NEDD4-2 
affects other downstream factors like NCC up-regulation and consequent compensatory 
mechanisms, or other factors involved in the control of ENaC function or trafficking (99), 
whereas mutations in the ENaC subunits would affect the channel directly. Thus, it would be 
of interest to generate Nedd4L knockout mice specifically in the CNT and CD, without 
targeting the DCT, to avoid the effects of NEDD4-2 loss on NCC expression and function, 
and thus see the impact on ENaC only. 
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Ubiquitylation and regulation of NCC-mediated Na+ reabsorption and blood pressure: 
an emerging field 
Given the relevance of NCC activity in human hypertension (90), many studies have focused 
on how NCC is regulated. It was first described in 2006 by Pacheco-Alvarez et al. that NCC 
phosphorylation on T53, T58 and S71 is crucial for its activity (68). Later, it was shown that 
the WNK pathway is implicated in both NCC phosphorylation and trafficking (59). WNK1, 
WNK4 and a third family member (WNK3) all activate SPAK/OSR1 that phosphorylate NCC 
and stimulate its activity (69, 76). In addition, WNK4 down-regulates NCC abundance at the 
cell surface, by promoting the lysosome-mediated degradation of the cotransporter (26, 42, 
103, 108). However, it has long remained unclear how NCC trafficking to the cell surface is 
regulated. Based on two independent in vitro studies, it has been proposed that WNK4 could 
divert NCC to the lysosomal pathway, possibly by regulating the interaction between the 
cotransporter and the lysosome-targeting receptor sortilin (111) and the AP3 adaptor complex 
(101). In PHAII patients, resulting from mutations in both WNK1 and WNK4 kinases, 
enhanced NCC phosphorylation and cell surface expression are observed, leading to increased 
Na+ reabsorption and hypertension (83, 109, 110). In contrast, WNK4-overexpressing 
transgenic mice develop characteristics of Gitelman’s syndrome characterized by decreased 
NCC expression and function (45). Intriguingly, total WNK4 knockout mice characterized by 
the group of Gerardo Gamba showed rather an incomplete form of Gitelman’s syndrome with 
decreased NCC expression, phosphorylation and activity, but without any changes in blood 
pressure and urinary calcium excretion (12).  
Aldosterone has been shown to increase NCC protein expression without affecting the NCC 
mRNA levels (1, 39, 63), suggesting a posttranslational mechanism. In the past few years, 
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many in vitro studies suggested that NCC ubiquitylation plays an important role in the 
regulation of the cotransporter. Ko et al. showed for the first time that NCC is internalized via 
a dynamin-dependent mechanism (42) and that this process is regulating NCC, resulting in a 
decreased activity of the cotransporter (43). They showed that the increased NCC 
ubiquitylation and decreased activity, observed after treating mDCT cells that endogenously 
express NCC with phorbol-ester, could be prevented using an E1 ubiquitin-activating enzyme 
inhibitor. Interestingly, a recent study showed that NCC phosphorylation prevents its 
ubiquitylation (31). In addition, Heise et al. showed that WNK1 and WNK4 phosphorylate 
NEDD4- 2 on the same sites as SGK1 does (30), suggesting that phosphorylation and 
ubiquitylation could regulate NCC concomitantly. Supporting this hypothesis, Arroyo et al. 
showed in vitro that NEDD4–2 co-immunoprecipitates with NCC and induces its 
ubiquitylation, decreasing the expression of the cotransporter at the plasma membrane and its 
activity. Moreover, like for ENaC regulation, SGK1 prevented the NEDD4–2 effect on NCC 
(3). There is also in vivo evidence that SGK1 is involved in NCC regulation (22, 23). The 
implication of NEDD4-2 in NCC regulation has now been confirmed in vivo with the 
generation of the Nedd4LPax8/LC1 knockout mouse model. Ronzaud et al. showed that NCC 
protein expression and phosphorylation were elevated in the Nedd4LPax8/LC1 knockout mice , 
as well as NCC function as the high blood pressure and hypercalciuria observed in the 
knockouts could be corrected by thiazide treatment (78). Taken together with the decreased 
αENaC and the absence of amiloride effect on the increased blood pressure, it was proposed 
that the elevated NCC-mediated Na+ reabsorption resulting from NEDD4-2 ablation is 
compensated by reduced ENaC function. Similarly, the increased NCC observed in the 
kidney-specific ks-wnk1 knockout mice was also compensated by down-regulation of the 
three ENaC subunits (28).  The observation that NEDD4-2 is involved in NCC regulation is 
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also supported by recent studies of a SNP in the NEDD4-2 gene, which appears to affect 
thiazide sensitivity (60). 
 
It has been shown that NEDD4 and NEDD4-like proteins can bind to and ubiquitylate target 
proteins that have no PY motif using PY-motif-containing adaptors (32, 47, 64).  Arroyo et al. 
showed that, in contrast to ENaC for which the NEDD4-2-mediated inhibition can be 
prevented when SGK1 phosphorylates NEDD4-2 on S328, the inhibition of NCC by the 
SGK1-NEDD4-2 pathway can be prevented by phosphorylation of NEDD4-2 on both S222 
and S328 sites (3).  The fact that NCC and ENaC are regulated by the SGK1-NEDD4-2 
pathway in a different manner and that NCC does not contain any PY motif suggest that 
NEDD4-2 controls NCC indirectly. Whether NCC and NEDD4-2 interact via an adaptor and 
its identity represent questions for further investigation.  
Interestingly, the Nedd4LPax8/LC1 knockout mice did not show all the PHAII characteristics, 
despite the strong NCC up-regulation. This contrasts with other mouse models for PHAII, like 
the PHAII-Wnk4 (Q562E) transgenic mice developed by Lalioti et al. In these mice, the 
elevated NCC and other PHAII features were abolished after breeding with NCC knockouts 
(45). Similarly, thiazide treatment of the Wnk4-D561A mutant mice developed by Yang et al. 
could prevent the increased NCC expression and phosphorylation and the associated 
hypertension and hyperkalemia (110). More and more studies suggest that PHAII cannot 
result from overactive NCC only, but rather from the misregulation of other channels and 
transporters. For instance, the ks-wnk1 knockouts described above display some but not all 
PHAII features (28). Moreover, NCC- overexpressing mice showed no increase in blood 
pressure or Ca2+ excretion (58). Finally, the increased ROMK protein expression in the 
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Nedd4LPax8/LC1 knockouts (78) may result in elevated K+ excretion, thus preventing the 
hyperkalemia normally observed in PHAII patients (28).  
Very interestingly, two other groups have recently identified another ubiquitin-protein ligase 
pathway affecting NCC cell surface abundance and involved in the pathology of PHAII, thus 
further supporting the importance of ubiquitylation in NCC regulation. Using exome 
sequencing, Boyden et al. identified mutations in two genes encoding the KLHL3 and CUL3 
proteins that led to PHAII (9). These two proteins are part of a Cullin-RING E3 ubiquitin-
protein ligase complex and, very interestingly, are expressed in DCT like NCC (9, 70). The 
same findings were reported by an independent group: Louis-Dit-Picard et al. also used 
combined whole-exome sequencing with linkage analysis and identified mutations in Kelch3 
that encodes the KLHL3 protein (48). They confirmed the co-expression of KLHL3 and NCC 
and showed in vitro that KLHL3 down-regulates NCC expression at the cell surface and that 
the reverse is observed after Kelch3 silencing. These recent findings strongly support the 
relevance of ubiquitylation in the control of NCC function.  
However, the observations that KLHL3 and CUL3 proteins down-regulate NCC expression at 
the cell surface do not prove the direct effect of these regulators on the cotransporter. Khan et 
al. have recently shown that phosphorylation of NCC controls its ubiquitylation and might 
play a role in NCC expression at the cell surface (31). In addition, some light has been very 
recently shed on the possible involvement of KLHL3/CUL3 in WNK1 or WNK4 
ubiquitylation (67, 88, 102, 106). It has been shown in vitro that the KLHL3/CUL3 complex 
interacts with WNK1 and WNK4, but not with NCC, and ubiquitylates and degrades the two 
WNK isoforms. Very interestingly, the WNK region, which interacts with KLHL3, is also 
that mutated in PHAII (67, 88).  
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Taken all these data together, we propose a model for the differential effect of ubiquitylation 
via NEDD4-2 or via KLHL3/CUL3 on NCC regulation in normal and pathological conditions 
(Figure 2). In conditions of RAAS activation (increased angiotensin II and aldosterone), NCC 
could be activated by phosphorylation via the WNKs and NEDD4-2-mediated ubiquitylation 
of NCC would be inhibited by SGK1 and possibly by the WNK kinases, thus maintaining 
sufficient NCC expression at the cell surface. In conditions of RAAS inactivation (decreased 
angiotensin II and aldosterone), NCC could be inactivated via two pathways: the 
KLHL3/CUL3 complex could interact with and ubiquitylate the WNKs, thus decreasing 
WNKs expression and resulting in decreased NCC phosphorylation and expression at the cell 
surface; in parallel, NEDD4-2 would ubiquitylate NCC and thus decrease its cell surface 
expression. In PHAII patients, mutations in either the WNKs or the KLHL3/CUL3 complex 
inhibit the interaction between the WNKs and the KLHL3/CUL3. As a result, WNK 
expression raises, leading to elevated NCC phosphorylation and expression. This results in 
elevated Na+ reabsorption, high blood pressure, RAAS inactivation, hypercalciuria and 
hyperkalemia. How the KLHL3/CUL3 and NEDD4-2 pathways interact with each other 
remains unknown. One hypothesis could be that the WNKs inhibit NEDD4-2 either directly 
or via SGK1 activation (30, 107). Finally, in case of NEDD4-2 ablation, NCC cannot be 
ubiquitylated and degraded, resulting in increased NCC surface expression and function, 
elevated Na+ reabsorption, high blood pressure, RAAS inactivation and hypercalciuria. In the 
Nedd4LPax8/LC1 knockout mice, the increased NCC was phosphorylated, indicating that the 
WNK pathway is activated (78). How the KLHL3/CUL3 and NEDD4-2 pathways interact 
with each other remains unknown. 
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Conclusions 
The recent studies in the field of ubiquitylation revealed the importance of this process in the 
regulation of Na+ reabsorption and blood pressure by the kidney. However, the importance of 
well-known ubiquitylated targets like ENaC has probably to be redefined, and novel targets 
like NCC are now emerging.  
Indeed, as discussed very recently by Ellison (20), there is more and more evidence 
suggesting that the absence of NEDD4-2-mediated ubiquitylation is not a prerequisite for up-
regulating ENaC (5, 78). The recent data in this field rather suggest that 1) the αENaC 
abundance (and thus ENaC function) is mainly regulated by aldosterone and that 2) the 
principal effect of NEDD4-2 on ENaC might be the regulation of the channel degradation 
inside the cell and not its removal from the cell surface. This last proposal should however be 
taken with precaution as others have suggested that ubiquitylation plays an important role in 
driving ENaC endocytosis (35). 
In fact, the recent studies have rather demonstrated the critical role of ubiquitylation in renal 
physiology by modulating the abundance of NCC. However, the underlying mechanisms of 
how NCC phosphorylation and ubiquitylation interact with each other to regulate NCC 
remain to be clarified. The observation that NEDD4-2 regulates NCC activity by 
ubiquitylation and reduction of  its surface expression (3, 78), whereas KLHL3/CUL3 seem to 
target WNK1/4 (67, 88, 102, 106), may lead to the hypothesis that NEDD4-2 regulates NCC 
activity via direct ubiquitylation, whereas KLHL3/CUL3 may act indirectly by ubiquitylating 
the NCC regulators, namely the WNKs, thus decreasing NCC phosphorylation. Importantly, 
inhibiting the NEDD4-2-NCC pathway appears not to be sufficient for resulting in a PHAII 
phenotype, whereas ablating the KLHL3/CUL3-WNK-NCC pathway does. Of interest, the 
work of Melanie Cobb has shown in vitro that the WNKs can inhibit NEDD4-2 either directly 
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or via SGK1 activation (30, 107). How exactly and in which physiological conditions the 
HECT ubiquitin-ligase NEDD4-2 pathway and the RING ubiquitin-ligases KLHL3 and CUL3 
pathway are involved in the modulation of NCC represent important questions for further 
investigation.  
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Figure legends  
Table 1. Comparative table of the different Nedd4-2 knockout mouse models.  
Figure 1. Model of NEDD4-2-mediated ubiquitylation of ENaC in normal and pathological 
conditions. A. In conditions of RAAS activation, aldosterone induces SGK1 expression that 
leads to phosphorylation and inhibition of NEDD4-2, thus disrupting the NEDD4-2/ENaC 
interaction and subsequent ubiquitylation and degradation of the channel. In parallel, 
misfolded or unassembled polyubiquitylated ENaC channels are degraded via the ubiquitin-
proteasome pathway in the ER in the context of ERAD (ER-associated degradation). The 
deubiquitinating enzymes (DUBs) are also involved in deubiquitylation and recycling of 
ENaC. B. In conditions of RAAS inactivation, aldosterone and SGK1 are low, whereas 
NEDD4-2 is highly expressed. NEDD4-2 ubiquitylates ENaC and leads either to degradation 
of the channel or to its recycling. It remains unclear whether NEDD4-2-mediated ENaC 
ubiquitylation happens on the channel at the cell surface or on the intracellular pool. C. In 
Liddle patients, mutations in the PY motifs of ENaC result in absence of interaction between 
ENaC and NEDD4-2 and thus defect in ubiquitylation and degradation of the channel, leading 
to permanently enhanced cell surface ENaC expression. D. In NEDD4LPax8/LC1 KO mice 
generated by Ronzaud et al. (78), it was shown that absence of NEDD4-2 protein expression 
leads to increased intracellular expression of βENaC and γENaC, but not αENaC. It was 
proposed that αENaC is regulated at the transcriptional level by aldosterone, thus leading to 
diminished ENaC activity to compensate increased NCC-mediated Na+ reabsorption (see 
Figure 2). 
Figure 2. Proposed model for the differential effect of ubiquitylation via NEDD4-2 or via 
KLHL3/CUL3 on NCC regulation in normal and pathological conditions. A. In conditions of 
RAAS activation, the WNK kinases phosphorylate and activate NCC and at the same time 
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SGK1, and possibly the WNKs, inhibit the NEDD4-2-mediated ubiquitylation of the co-
transporter, thus maintaining sufficient NCC expression at the cell surface. B. In conditions of 
RAAS inactivation, NCC is inactivated via two pathways: the KLHL3/CUL3 complex 
ubiquitylates the WNKs, thus decreasing WNKs expression and resulting in decreased NCC 
phosphorylation and expression at the cell surface; in parallel, NCC is ubiquitylated by 
NEDD4-2, which decreases its cell surface expression. C. In PHAII patients, mutations in 
either the WNKs or the KLHL3/CUL3 complex inhibit the interaction between the WNKs 
and the KLHL3/CUL3. This results in a raise of WNKs expression, leading to elevated NCC 
phosphorylation and expression. This leads to elevated Na+ reabsorption andblood pressure, 
RAAS inactivation, hypercalciuria and hyperkalemia. D. In case of NEDD4-2 ablation, NCC 
cannot be ubiquitylated and degraded, resulting in increased NCC surface expression and 
function, elevated Na+ reabsorption and blood pressure, RAAS inactivation and 
hypercalciuria.  
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Table 1.  
 
 
 
n.d.: not determined; n.c.: not changed; HT: hypertension; +/-: heterozygous. 
 
 
 
  Shi et al, 2009 Boase et al, 2011 Kimura et al, 2011 Ronzaud et al, 2013 
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72kD : n.d.                                           
46kD : present (Boase et al, 2011) 
125kD : absent                    
110kD : absent 
46kD : absent 
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R
en
al
  p
he
no
ty
pe
 Aldosterone Standard / high-Na
+ : n.c.                    
Low-Na+ : ↑ 
n.d. n.d. Standard / high-Na+ : ↓  
Blood pressure ENaC-dependent                                  
salt-sensitive HT 
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